Printer Friendly

SURVIVAL ANALYSIS FROM SATRAPLATIN TRIAL DISAPPOINTING.

Martinsried/Munich (Germany), Princeton, N.J. and Boulder, Colo., October 30, 2007 - GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ: GPCB) and Pharmion Corporation (NASDAQ: PHRM) has announced topline overall survival results for the double-blinded, randomized satraplatin Phase 3 registrational trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer). The trial evaluated satraplatin plus prednisone versus placebo plus prednisone as a second-line treatment in 950 patients with hormone-refractory prostate cancer (HRPC). The companies reported that the trial did not achieve the endpoint of overall survival (p=3D0.80, stratified log rank analysis). The median was 61.3 weeks for the satraplatin arm compared to 61.4 weeks for the control group and the hazard ratio was 0.97 (95% CI: 0.83, 1.13). The companies are currently conducting pre-specified subset analyses.

Based on the recent results announced, GPC Biotech is re- evaluating its development plans for satraplatin, including SPERA, the Satraplatin Expanded Rapid Access protocol in the U.S.

"We are extremely disappointed with the findings we announced today," said Bernd R. Seizinger, M.D., Ph.D., CEO of GPC Biotech. "We are currently discussing with our partners, Pharmion and Yakult, plans for the future development of satraplatin. I would like to warmly thank and recognize the contributions of the investigators and patients, as well as their families, who participated in the SPARC trial."

"These results are clearly disappointing and will impact the EMEA review of our current Marketing Authorization Application for satraplatin," said Patrick J. Mahaffy, president and CEO of Pharmion Corporation. "The key for our European submission now will be to conduct the pre-specified subset analyses and particularly to focus on the impact of prior Taxotere(R) use, which we know is very important to the EMEA."

Pharmion's Marketing Authorization Application with the European Medicines Agency (EMEA) for satraplatin in combination with prednisone for the treatment of patients with metastatic HRPC who have failed prior chemotherapy was submitted in June 2007. The submission, based on the statistically significant progression-free survival results announced in September 2006, was timed so that overall survival data could be submitted during the review process. Pharmion plans to review the additional analyses and work closely with the EMEA to determine next steps for the filing.

About GPC Biotech

GPC Biotech AG is a publicly traded biopharmaceutical company focused on discovering, developing and commercializing new anticancer drugs. GPC Biotech's lead product candidate is satraplatin, an oral platinum compound. The company has various anti-cancer programs in research and development that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany) and has a wholly owned U.S. subsidiary headquartered in Princeton, New Jersey.

For more information, http://www.gpc-biotech.com or call 609/524-5884.

About Pharmion

Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent.

For more information, visit http://www.pharmion.com or call 720/564-9150.
COPYRIGHT 2007 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Date:Dec 1, 2007
Words:525
Previous Article:SNT-MC17 PHASE IIA FOR MUSCULAR DYSTROPHY ENCOURAGING.
Next Article:QRXPHARMA BEGINS PHASE III CLINICAL TRIAL FOR PAIN THERAPY.
Topics:


Related Articles
GBC BIOTECH PRESENTS NEW DATA ON EFFICACY OF SATRAPLATIN.
GPC BIOTECH GETS U.S. PATENT FOR ANTI-CANCER CELL INHIBITOR.
GPC BIOTECH/DEBIOPHARM SIGN MHC II ANTAGONISTS LICENSE PACT.
GPC BIOTECH PRESENTS NEW SATRAPLATIN DATA AT AACR.
SATRAPLATIN REDUCES RISK OF PROSTATE CANCER PROGRESSION.
ON THE DASHBOARD > TACO BELL CHILI CHEESE NACHOS BELL GRANDE.
UCB INITIATES PHASE III RIKRLTS TRIAL FOR EPILEPSY.
BIOLINERX REPORTS POSITIVE RESULTS FROM BL-1020 TRIAL.
SNT-MC17 PHASE IIA FOR MUSCULAR DYSTROPHY ENCOURAGING.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters